Canonical: https://ownershiptrace.com/13f/companies/1288

# Who owns Protagonist Therapeutics, Inc (PTGX)? Elite investor 13F holders

3 tracked elite investors reported holding Protagonist Therapeutics, Inc as of 2026-06-30, including Polen Capital Management, Gotham Asset Management, Bridgewater Associates. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in…

## Reported holders and securities, including exits (up to 20)

| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|  --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| [Rubric Capital](https://ownershiptrace.com/13f/investors/120) | PROTAGONIST THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | [Original filing](https://www.sec.gov/Archives/edgar/data/1687509/0001104659-26-097098-index.html) |
| [Duquesne Family Office](https://ownershiptrace.com/13f/investors/30) | PROTAGONIST THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | [Original filing](https://www.sec.gov/Archives/edgar/data/1536411/0001536411-26-000006-index.html) |
| [Polen Capital Management](https://ownershiptrace.com/13f/investors/61) | PROTAGONIST THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-04 00:00:00 | 2776560.00 USD | 22651.000000 | Shares | reduce | [Original filing](https://www.sec.gov/Archives/edgar/data/1034524/0001172661-26-003035-index.html) |
| [Gotham Asset Management](https://ownershiptrace.com/13f/investors/94672) | PROTAGONIST THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 2287711.00 USD | 18663.000000 | Shares | reduce | [Original filing](https://www.sec.gov/Archives/edgar/data/1510387/0001398344-26-014644-index.html) |
| [Bridgewater Associates](https://ownershiptrace.com/13f/investors/8) | PROTAGONIST THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1136194.00 USD | 9269.000000 | Shares | add | [Original filing](https://www.sec.gov/Archives/edgar/data/1350694/0001350694-26-000003-index.html) |

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

[How to read the data](https://ownershiptrace.com/docs#reading-the-data) · [Disclaimer](https://ownershiptrace.com/disclaimer)